Phase 0 trials/ Intra-Target-Microdosing (ITM) and the lung: a review
BMC Pulmonary Medicine September 1, 2024 Tom M. Quinn, Annya M. Bruce, Tal Burt et al.
Abstract The COVID-19 pandemic has highlighted the importance of efficient drug discovery in respiratory disease. The traditional set up of clinical trials is expensive and allows for significant attrition of new drugs, many of which undergo extensive safety testing before being abandoned for lack of efficacy. Phase 0 trials, named as they sit between pre-clinical research and phase I, allow...